Ischemia Technologies, Inc.
This article was originally published in The Gray Sheet
Executive Summary
Albumin Cobalt Binding (ACB) in vitro diagnostic blood test gains FDA market clearance for use with troponin protein tests and an electrocardiogram to help rule out a heart attack. About 3 mil.-5 mil. Americans present at emergency rooms each year with symptoms. A 200-patient study showed that the ACB lab test increased accuracy in ruling out heart attacks to 70% from 50% without ACB...
You may also be interested in...
UK Medtech Strategy Sets Out Schedule Of Milestones To FY 2026
Fourteen months on from the release of its inaugural medtech strategy, the UK MedTech Directorate has laid firm foundations and reports progress on initiatives aimed at improving technology adoption. A schedule of ambitious future timelines has also been published.
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.